01:45 , Nov 17, 2018 |  BioCentury  |  Product Development

MyoKardia’s myosin mechanism deconvolution

With preclinical proof of concept that its lead candidate mavacamten acts via two distinct mechanisms to treat cardiomyopathy, MyoKardia Inc. is ready to accelerate a pipeline of preclinical programs that exploit the mechanisms separately for...
20:04 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

MyoKardia's heart failure candidate shows proof of mechanism in Phase Ia

MyoKardia Inc. (NASDAQ:MYOK) reported data from a Phase Ia trial in healthy volunteers showing that heart failure candidate MYK-491 increased cardiac contractility by 5-20% across multiple echocardiographic parameters with minimal effect on diastolic function. The...
18:25 , May 25, 2018 |  BC Week In Review  |  Financial News

MyoKardia prices $184M follow-on

MyoKardia Inc. (NASDAQ:MYOK) raised $183.8 million late on May 22 through the sale of 3.8 million shares at $49 in a follow-on underwritten by J.P. Morgan, BofA Merrill Lynch, Credit Suisse and Wells Fargo. The...
16:48 , May 23, 2018 |  BC Extra  |  Financial News

MyoKardia prices $184M follow-on

MyoKardia Inc. (NASDAQ:MYOK) raised $183.8 million late Tuesday through the sale of 3.8 million shares at $49 in a follow-on underwritten by J.P. Morgan, BofA Merrill Lynch, Credit Suisse and Wells Fargo. The price is...
00:46 , Apr 28, 2018 |  BioCentury  |  Strategy

The outsiders

As he retires from Sanofi, Elias Zerhouni has advice for the biopharma industry: the traditional executive mold must be expanded. On April 24, Sanofi announced Zerhouni would retire on June 30 and that John Reed,...
16:42 , Mar 16, 2018 |  BC Week In Review  |  Clinical News

MyoKardia's mavacamten meets in low-dose cohort of Phase II for cardiomyopathy

MyoKardia Inc. (NASDAQ:MYOK) reported data from the 10 patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM) in the second cohort of the open-label, U.S. Phase II PIONEER-HCM trial showing that lower doses of oral mavacamten met...
18:57 , Oct 27, 2017 |  BC Week In Review  |  Clinical News

Cytokinetics begins Phase III CVOT trial of omecamtiv mecarbil

Cytokinetics Inc. (NASDAQ:CYTK) began the Phase III GALACTIC-HF cardiovascular outcomes trial (CVOT) trial evaluating twice-daily oral omecamtiv mercarbil (AMG 423) in about 8,000 patients with high-risk chronic heart failure and reduced ejection fraction. The double-blind,...
15:43 , Aug 11, 2017 |  BC Week In Review  |  Clinical News

MyoKardia's mavacamten meets in Phase II for HCM

MyoKardia Inc. (NASDAQ:MYOK) reported top-line data from 10 evaluable patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM) in the first cohort of the Phase II PIONEER-HCM trial showing that once-daily 10 or 15 mg mavacamten met...
20:31 , Aug 9, 2017 |  BC Extra  |  Financial News

MyoKardia prices follow-on as stock momentum continues

MyoKardia Inc. (NASDAQ:MYOK) crept up $0.55 to $36.75 on Wednesday after it raised $124.3 million through the sale of 3.5 million shares at $35.50 in a follow-on underwritten by JPMorgan, Cowen, BMO Capital Markets and...
20:59 , Aug 7, 2017 |  BC Extra  |  Clinical News

MyoKardia to raise funds after reporting HCM data

MyoKardia Inc. (NASDAQ:MYOK) proposed to sell 3.5 million shares in a follow-on after market close on Monday after reporting earlier in the day that lead candidate mavacamten (formerly MYK-461) met the primary endpoint in the...